RCRamón Corbalán

Ramón Corbalán

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ramón Corbalán has a total of 207 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Fibrilación auricular una arritmia y un sindrome

    by Ramón Corbalán

    La forma más común de FA, relacionada con el envejecimiento, es un proceso de remodelado estructural con depósito de tejido conectivo y fibrosis de la aurícula izquierda (AI), que es seguida por alteraciones de las propiedades eléctricas que facilitan el origen y la perpetuación de la arritmia2. La FA suele ser precipitada por un fenómeno inflamatorio. En trabajos previos reportamos que el biomarcador inflamatorio, proteína C reactiva (PCR), junto con un marcador de disfunción endotelial, trombomodulina soluble, son marcadores de perpetuación o remisión de la arritmia en pacientes con FA reciente3. Con posterioridad evaluamos predictores de FA postoperatoria de cirugía cardíaca y encontramos que otro factor de disfunción endotelial, la proteína soluble de adhesión celular vascular (sVCAM-1) es también un predictor independiente de FA4.


  • Gliflozins and Atrial Fibrillation

    by Ramon Corbalan, Mónica Acevedo

  • Open Access

    Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial

    by Scott D Solomon, Brian L Claggett, Zi Michael Miao, Rafael Diaz, G Michael Felker, John J V McMurray, Marco Metra, Ramon Corbalan, Gerasimos Filippatos, Assen R Goudev, et al.

    In GALACTIC-HF, the cardiac myosin activator omecamtiv mecarbil compared with placebo reduced the risk of heart failure events or cardiovascular death in patients with heart failure with reduced ejection fraction. We explored the influence of atrial fibrillation or flutter (AFF) on the effectiveness of omecamtiv mecarbil. GALACTIC-HF enrolled patients with New York Heart Association (NYHA) Class II–IV heart failure, left ventricular ejection fraction ≤35%, and elevated natriuretic peptides. We assessed whether the presence or absence of AFF, a pre-specified subgroup, modified the treatment effect for the primary and secondary outcomes, and additionally explored effect modification in patients who were or were not receiving digoxin. Patients with AFF (n = 2245, 27%) were older, more likely to be randomized as an inpatient, less likely to have a history of ischaemic aetiology or myocardial infarction, had a worse NYHA class, worse quality of life, lower estimated glomerular filtration rate, and higher N-terminal pro-B-type natriuretic peptide. The treatment effect of omecamtiv mecarbil was modified by baseline AFF (interaction P = 0.012), with patients without AFF at baseline deriving greater benefit. The worsening of the treatment effect by baseline AFF was significantly more pronounced in digoxin users than in non-users (interaction P = 0.007); there was minimal evidence of effect modification in those patients not using digoxin (P = 0.47) or in digoxin users not in AFF. Patients in AFF at baseline were less likely to benefit from omecamtiv mecarbil than patients without AFF, although the attenuation of the treatment effect was disproportionally concentrated in patients with AFF who were also receiving digoxin. Clinical Trial Registration: NCT02929329 In GALACTIC-HF, patients with atrial fibrillation or flutter (AFF) at baseline derived less benefit from Omecamtiv Mecarbil than patients not in AFF. This finding was primarily driven by those patients in AFF who were taking digoxin.


  • Open Access

    Otimizando o Tratamento para o Infarto Agudo do Miocárdio, um Esforço Contínuo

    by Ramón Corbalán

    A reperfusão precoce com intervenção coronária percutânea primária (ICPP) ou trombólise (TL) diminuiu a morbimortalidade por infarto agudo do miocárdio (IAM) na América Latina e no mundo. Diretrizes nacionais e internacionais recomendam a reperfusão, por qualquer um dos métodos, de acordo com a disponibilidade no centro médico, para pacientes internados em até 12 horas desde o início dos sintomas de IAM., A ICPP tem se mostrado superior à TL, principalmente quando realizada em um centro de atendimento especializado com infraestrutura,


  • Open Access

    Bernard Lown y El Arte de Sanar

    by Ramón Corbalán

    Se presenta una semblanza del Dr. Bernard Lown, uno de los más destacados cardiólogos del siglo XX.

  • Open Access

    Preoperative solubleVCAM-1 contributes to predict late mortality after coronary artery surgery

    by Ramon Corbalan, Mauricio Garcia, Luis Garrido‐Olivares, Lorena Garcia, Gonzalo Perez, Rosemarie Mellado, Ricardo Zalaquett, Mario Chiong, Jorge Quitral, Sergio Lavandero

    Background Soluble vascular cell adhesion molecule-1 has been associated with long-term cardiovascular mortality in patients with stable coronary artery disease and to the development of new atrial fibrillation in subjects with cardiovascular risk factors but no evidence of cardiac disease. Hypothesis Preoperative soluble vascular cell adhesion molecule-1 predicts the risk of future all-cause death and cardiovascular death among patients submitted to elective coronary artery bypass surgery. Methods From a cohort of 312 patients who underwent elective coronary artery bypass surgery prospectively followed for a median of 6.7 years, we evaluated the prognostic role of preoperative soluble vascular cell adhesion molecule-1, inflammatory markers, CHA2DS2-VASc score and development of postoperative atrial fibrillation (POAF). Univariable and multivariable Cox regression analyses were performed to establish an association of these parameters with long term all-cause death and cardiovascular death. Results During 2112 person-years of follow-up, we observed 41 deaths, 10 were cardiovascular deaths. Independently increased levels of preoperative soluble vascular cell adhesion molecule-1, POAF, and CHA2DS2-VASc score were associated with all-cause mortality. After multivariate adjustment, elevated preoperative soluble vascular cell adhesion molecule-1 and POAF were the only independent predictors of all-cause death. Also, preoperative soluble vascular cell adhesion molecule-1, POAF, and CHA2DS2-VASc score resulted in being independent predictors of cardiovascular mortality. Conclusions Increased circulating levels of preoperative soluble vascular cell adhesion molecule-1, together with POAF and CHA2DS2-VASc score, were significantly associated with future all-cause death and cardiovascular death among patients submitted to coronary artery bypass surgery.


  • Open Access

    Cardiorespiratory fitness improves prediction of mortality of standard cardiovascular risk scores in a Latino population

    by Mónica Acevedo, Giovanna Valentino, María José Bustamante, Lorena Orellana, Marcela Adasme, Fernando Baraona, Ramón Corbalán, Carlos Navarrete

    Background: Cardiorespiratory fitness (CRF) is a powerful predictor of mortality. This study evaluated the predictive value of CRF for mortality in Chilean subjects without atherosclerotic disease compared with the Framingham, European Systematic Coronary Risk Evaluation (SCORE), and 2013 ACC/AHA risk scores and determined the incremental predictive value of CRF when added to these scores.Hypothesis: CRF improves prediction of all‐cause and cardiovascular disease (CVD)‐related mortality of the standard international risk scores.Methods: Cross‐sectional study, which evaluated 4064 subjects between 2002 and 2016. Cardiovascular (CV) risk factors, anthropometric and biochemical parameters, and blood pressure were measured. CRF was determined by metabolic equivalents during maximum stress test. The Framingham, SCORE, and ACC/AHA risk scores were calculated for all subjects. After a median follow‐up of 9 years, all‐cause and CVD‐related mortality were assessed. Receiver operating curves were built to determine mortality prediction for CRF, the risk scores, and CRF added to the scores.Results: As of August 2016, 99 deaths were reported, 33 of which were CVD‐related. All risk scores and CRF predicted CVD‐related mortality, with CRF identified as the best predictor: CRF: C = 0.88 (95% CI: 0.82‐0.93) vs Framingham: C = 0.68 (95% CI: 0.60‐0.76), SCORE: C = 0.76 (95% CI: 0.70‐0.83), and ACC/AHA: C = 0.79 (95% CI: 0.73‐0.85). Predictive power of the three scores improved when CRF was added to the model, but this was only significant for the Framingham score.Conclusions: CRF is a good predictor of both, all‐cause and CV mortality and a better predictor of CVD‐related deaths than standard risk scores in this population.


  • Open Access

    Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation

    by Ramon Corbalan, Jean-Pierre Bassand, Laura Illingworth, Giuseppe Ambrosio, A. John Camm, David A. Fitzmaurice, Keith A. A. Fox, Samuel Z. Goldhaber, Shinya Goto, Sylvia Haas, et al.

    Congestive heart failure (CHF) is commonly associated with atrial fibrillation (AF), and their combined presentation confers a worse prognosis than either condition alone.1 Treatment of both conditions implies use of specific drugs for CHF plus antithrombotic agents for stroke prevention. In addition, management strategies and outcomes may be affected by the etiology of CHF, namely ischemic cardiomyopathy (ICM) or nonischemic cardiomyopathy (NICM) because the prescription of antithrombotic therapies might be different and could affect prognosis in terms of death, stroke/systemic embolism (SE), and bleeding.2,3 The aim of our study was to assess the treatment strategies in terms of antithrombotic and CHF therapies and 1-year clinical outcomes in patients with newly diagnosed AF and concomitant CHF stratified by etiology (ICM vs NICM) enrolled in the Global Anticoagulant Registry in the Field–Atrial Fibrillation (GARFIELD-AF) registry.


  • Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation

    by Ramón Corbalán, José Carlos Nicolau, José López-Sendon, Armando Garcia-Castillo, Rodrigo Botero, Gustavo Sotomora, Manuel Horna, Christian T. Ruff, Rose A. Hamershock, Laura T. Grip, et al.


  • Open Access

    Características basales, manejo de terapias antitrombóticas y pronóstico de pacientes chilenos con FA no valvular. Lecciones del Registro GARFIELD AF en Chile

    by Ramón Corbalán, Carlos Conejeros, Carlos Rey, Benjamín Stockins, Germán Eggers, Carlos Astudillo, Fernando Lanas, Sergio Potthoff, César Houzvic, Humberto Montecinos, et al.

    La prevalencia de FA en Latinoamérica es similar a la reportada en grandes estudios epidemiológicos. Se estima que afecta a 1,6% de la población global, variando desde 0,4% en edades menores de 50 años hasta 8,26% sobre la edad de 80 años, con 75% de casos observados en adultos mayores de 60 años4.